Mosaic ImmunoEngineering, Inc.

Equities

CPMV

US61945M1018

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:18:57 2024-04-24 pm EDT			5-day change	1st Jan Change
0.3131 ^USD	+0.03%		-22.11%	-47.82%

Apr. 15	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 28	Mosaic ImmunoEngineering, Inc. Receives Letter of Termination from CWRU	CI

Mosaic ImmunoEngineering Inc. Auditor Raises 'Going Concern' Doubt

March 01, 2023

Mosaic ImmunoEngineering Inc. filed its 10-K on Mar 02, 2023 for the period ending Dec 31, 2022. In this report its auditor, KMJ Corbin & Company LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Mosaic ImmunoEngineering, Inc.

Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Mosaic ImmunoEngineering, Inc. Receives Letter of Termination from CWRU	Mar. 28	CI
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Mosaic Immunoengineering, Inc. Announces Nicole Steinmetz, Ph.D., to Resign as A Member of the Board of Directors and Acting Chief Scientific Officer	23-05-03	CI
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-02	CI
Mosaic ImmunoEngineering Inc. Auditor Raises 'Going Concern' Doubt	23-03-01	CI
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-01	CI
Mosaic ImmunoEngineering Inc. Academic Collaborators Receives Grants Totaling $4.3 Million from NCI Focuses on its Novel Immuno-Oncology Platform	22-10-31	CI
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Mosaic ImmunoEngineering Inc. announced that it expects to receive $5 million in funding	22-02-17	CI
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-01-26	CI
Mosaic ImmunoEngineering Inc. Auditor Raises 'Going Concern' Doubt	22-01-25	CI
Mosaic ImmunoEngineering Inc. Announces Board Changes	21-06-15	CI
Mosaic ImmunoEngineering Inc. announced that it has received $0.675 million in funding	21-05-06	CI
Mosaic Immunoengineering Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-05	CI
Mosaic ImmunoEngineering Inc. Announces Fiscal Year End Change	20-12-30	CI
Patriot Scientific Corporation has Changed its Name to Mosaic ImmunoEngineering Inc	20-11-30	CI
Patriot Scientific Corporation Enter into Offer Letter with Paul Lytle Chief Financial Officer	20-11-19	CI
Patriot Scientific Corporation Enter into Offer Letter with Steven King, President and Paul Lytle, Executive Vice President	20-11-19	CI
Patriot Scientific Corporation Enter into Offer Letter with Steven King Chief Executive Officer	20-11-19	CI
Mosaic ImmunoEngineering Inc acquired Patriot Scientific Corporation for $30.3 million in a reverse merger transaction.	20-08-23	CI

Chart Mosaic ImmunoEngineering, Inc.

Duration

Period

More charts

Company Profile

Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company. The Company is focused on developing and commercializing its immunomodulator platform technology. The Companyâs core technology platform is based on Cowpea mosaic virus (CPMV), which is non-infectious to humans or other animals but upon intra-tumoral administration, elicits an innate immune response resulting in potent antitumor activity against the primary and distant tumor sites. The Companyâs lead immunotherapy product candidate, MIE-101, is based on a naturally occurring plant virus known as CPMV. The product is injected directly into a tumor and can act as an in-situ vaccine using markers of the injected tumor as the target which results in the activation of an immune response against the primary tumor and to prime systemic anti-tumor immunity, while reversing immunosuppressive signals in the tumor microenvironment (TME). MIE-101 is used for the treatment of many different types of cancer.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MOSAIC IMMUNOENGINEERING, INC.	-47.82%	2.27M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research